A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma
Capmatinib + BEV was well-tolerated but had no clear signal of activity in c-MET non-activated high-grade glioma.
Authors
- Lindsey Finney (ORCID: https://orcid.org/0000-0002-6046-6764)
- Mythili Shastry (ORCID: https://orcid.org/0000-0003-2445-8094)
- Ming‐Chieh Shih (ORCID: https://orcid.org/0000-0002-8610-5916)
- James Battiste
- Gerald S. Falchook (ORCID: https://orcid.org/0000-0001-9165-2191)
- Susan Hoekstra (ORCID: https://orcid.org/0000-0001-5767-2674)
- Kent C. Shih (ORCID: https://orcid.org/0000-0002-6718-6116)
- Amandeep Kalra
Institutions
- Oklahoma City University (US)
- HCA Midwest Division (US)
- Sarah Cannon (US)
- Tennessee Oncology (US)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1093/noajnl/vdae220
- Citations
- 3
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.31